Extractables and Leachables USA 2015, organized by Smithers Rapra, will be coming to Bethesda, MD on May 12-14 2015 at the Doubletree by Hilton Hotel Bethesda. Following last year's success in Silver Spring, the 2015 forum will provide delegates with another unique opportunity to come together to discuss all current E&L issues facing the pharmaceutical industry.
E&L USA will feature the latest developments from industry practitioners and working groups to meet regulatory requirements and ensure compatibility in drug-package combinations plus the latest information on regulatory updates, scientific based strategies and practical approaches for the evaluation of extractables and leachables for pharmaceutical packaging materials. Additionally, the extensive networking and social agenda set to feature at the conference will provide a valuable knowledge-sharing experience for delegates.
Smithers Rapra are now recruiting papers from experts and companies that have established best practice in the field of extractables and leachables. Organisations presenting a paper at this conference will have the opportunity to present to all parts of the pharmaceutical supply chain and will be firmly positioning themselves at the forefront of E&L activity. Submitted abstracts will be reviewed by the expert programme advisory board, consisting of representatives from Pfizer, Boehringer Ingelheim, West Pharma and Smithers Rapra's own E&L expert Dr Andrew Feilden.
For more information or to submit a proposed paper title and short abstract, please contact Conference Producer Hayley Marsden, +44(0)1372 802026, email@example.com. The deadline for proposed papers is January 7, 2015.
The following topics will be particularly relevant to the direction of the conference, however all submitted themes will be considered:
- supply chain management;
- toxicology of possible leachables;
- single use systems;
- risk assessment methodologies relating to E&L strategies.
- detection limits;
- application of E&L to QC testing programs;
- restricted and regulated substance compliance;
- E&Ls and biologicals;
- manufacture of pharmaceutical packaging and labelling;
- improvements in practical correlation of solvent extractions to product conditions of use;
- E&Ls in process components and equipment.